Celldex Therapeutics, Inc. — Director's Dealing 2025

Nov 17, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2025-11-13

Reporting Person: Wright Richard M. (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-11-13	Common Stock	M	6876	$9.0165	Acquired	27709	Direct
2025-11-13	Common Stock	M	26672	$10.38	Acquired	54381	Direct
2025-11-13	Common Stock	M	15750	$22.48	Acquired	70131	Direct
2025-11-13	Common Stock	S	49298	$24.0005	Disposed	20833	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-11-13	Incentive Stock Option	$9.0165	M	6876	Disposed	2028-06-13	Common Stock (6876)	Direct
2025-11-13	Incentive Stock Option	$10.38	M	26672	Disposed	2030-06-18	Common Stock (26672)	Direct
2025-11-13	Incentive Stock Option	$22.48	M	15750	Disposed	2032-06-16	Common Stock (15750)	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.00 to $24.05 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F2: As of June 13, 2022, the option is fully vested.

F3: As of June 18, 2024, the option is fully vested.

F4: 25% vested on June 16, 2023 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.